Stock Scorecard
Stock Summary for Celldex Therapeutics Inc (CLDX) - $20.66 as of 5/5/2025 2:46:11 PM EST
Total Score
7 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLDX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLDX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLDX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CLDX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CLDX (37 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CLDX
Financial Details for CLDX
Company Overview |
|
|---|---|
| Ticker | CLDX |
| Company Name | Celldex Therapeutics Inc |
| Country | USA |
| Description | Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey. |
| Sector Name | LIFE SCIENCES |
| Industry Name | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 5/5/2025 |
Stock Price History |
|
| Last Day Price | 20.66 |
| Price 4 Years Ago | 38.64 |
| Last Day Price Updated | 5/5/2025 2:46:11 PM EST |
| Last Day Volume | 598,699 |
| Average Daily Volume | 811,594 |
| 52-Week High | 47.00 |
| 52-Week Low | 14.40 |
| Last Price to 52 Week Low | 43.47% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 29.85 |
| Sector PE | 37.03 |
| 5-Year Average PE | -13.53 |
| Free Cash Flow Ratio | 48.05 |
| Industry Free Cash Flow Ratio | 85.95 |
| Sector Free Cash Flow Ratio | 29.42 |
| Current Ratio Most Recent Quarter | 18.91 |
| Total Cash Per Share | 0.43 |
| Book Value Per Share Most Recent Quarter | 11.25 |
| Price to Book Ratio | 1.84 |
| Industry Price to Book Ratio | 9.86 |
| Sector Price to Book Ratio | 21.93 |
| Price to Sales Ratio Twelve Trailing Months | 195.37 |
| Industry Price to Sales Ratio Twelve Trailing Months | 6.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 28.34 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 66,384,000 |
| Market Capitalization | 1,371,493,440 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.16% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -11.62% |
| Reported EPS 12 Trailing Months | -2.45 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -2.45 |
| Net Income Twelve Trailing Months | -157,863,000 |
| Net Income Past Year | -157,863,000 |
| Net Income Prior Year | -141,429,000 |
| Quarterly Revenue Growth YOY | -71.60% |
| 5-Year Revenue Growth | 14.46% |
| Operating Margin Twelve Trailing Months | -4,768.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 28,356,000 |
| Total Cash Past Year | 28,356,000 |
| Total Cash Prior Year | 34,814,000 |
| Net Cash Position Most Recent Quarter | 28,356,000 |
| Net Cash Position Past Year | 28,356,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 747,005,000 |
| Total Stockholder Equity Prior Year | 429,171,000 |
| Total Stockholder Equity Most Recent Quarter | 747,005,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -159,770,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.41 |
| Free Cash Flow Past Year | -159,697,000 |
| Free Cash Flow Prior Year | -109,109,000 |
Options |
|
| Put/Call Ratio | 1.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.43 |
| MACD Signal | -0.07 |
| 20-Day Bollinger Lower Band | 15.95 |
| 20-Day Bollinger Middle Band | 21.70 |
| 20-Day Bollinger Upper Band | 27.45 |
| Beta | 1.59 |
| RSI | 58.59 |
| 50-Day SMA | 29.30 |
| 150-Day SMA | 33.21 |
| 200-Day SMA | 34.54 |
System |
|
| Modified | 5/5/2025 8:44:29 PM EST |